NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

Search

Coloplast A-S (Class B)

Open

492.5 2.65

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

481.7

Max

494.8

Belangrijke statistieken

By Trading Economics

Inkomsten

522M

1.4B

Verkoop

83M

7B

K/W

Sectorgemiddelde

27.421

110.024

EPS

6.32

Dividendrendement

4.84

Winstmarge

19.835

Werknemers

16,983

EBITDA

309M

2.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+11.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.84%

2.26%

Volgende Winsten

12 mei 2026

Volgende dividenddatum

20 mei 2026

Volgende Ex Dividend datum

18 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-9.1B

110B

Vorige openingsprijs

489.85

Vorige sluitingsprijs

492.5

Coloplast A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb 2026, 22:36 UTC

Winsten

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb 2026, 22:32 UTC

Winsten

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb 2026, 23:58 UTC

Marktinformatie
Winsten

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb 2026, 23:58 UTC

Marktinformatie
Winsten

Global Energy Roundup: Market Talk

23 feb 2026, 23:47 UTC

Marktinformatie

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb 2026, 23:43 UTC

Marktinformatie

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb 2026, 23:41 UTC

Acquisities, Fusies, Overnames

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb 2026, 23:40 UTC

Marktinformatie

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb 2026, 23:39 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb 2026, 23:31 UTC

Winsten

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb 2026, 23:31 UTC

Winsten

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb 2026, 23:27 UTC

Winsten

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb 2026, 23:24 UTC

Marktinformatie

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb 2026, 22:31 UTC

Winsten

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 22:24 UTC

Winsten

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb 2026, 22:21 UTC

Winsten

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb 2026, 22:21 UTC

Winsten

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb 2026, 22:20 UTC

Winsten

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Vergelijking

Prijswijziging

Coloplast A-S (Class B) Prognose

Koersdoel

By TipRanks

11.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 901.38 DKK  11.86%

Hoogste 1,056 DKK

Laagste 720 DKK

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Coloplast A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

2

Buy

4

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat